Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to 0.19%.

  • Dexcom's Return on Capital Employed rose 200.0% to 0.19% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.19%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.21% for FY2025, which is 400.0% up from last year.
  • Per Dexcom's latest filing, its Return on Capital Employed stood at 0.19% for Q4 2025, which was up 200.0% from 0.19% recorded in Q3 2025.
  • In the past 5 years, Dexcom's Return on Capital Employed ranged from a high of 0.19% in Q4 2025 and a low of 0.05% during Q2 2022
  • Its 5-year average for Return on Capital Employed is 0.12%, with a median of 0.11% in 2023.
  • In the last 5 years, Dexcom's Return on Capital Employed crashed by -300bps in 2022 and then skyrocketed by 600bps in 2025.
  • Dexcom's Return on Capital Employed (Quarter) stood at 0.06% in 2021, then soared by 84bps to 0.12% in 2022, then increased by 4bps to 0.12% in 2023, then skyrocketed by 40bps to 0.17% in 2024, then increased by 11bps to 0.19% in 2025.
  • Its Return on Capital Employed stands at 0.19% for Q4 2025, versus 0.19% for Q3 2025 and 0.18% for Q2 2025.